Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingya Li

Showing results (21-30 of 146) with videos related to

Pageof 15
Sort By:
Immunology|August 18, 2004
Thymocytes induced by antigen injection into the anterior chamber activate splenic CD8+ suppressor cells and enhance the antigen-induced production of immunoglobulin G1 antibodiesXingya Li, Yafei Wang, David Urso, et al.
Immunology|October 21, 2006
The suppression of delayed-type hypersensitivity by CD8+ regulatory T cells requires interferon-gammaRobert E Cone, Xingya Li, Roshanak Sharafieh, et al.
Cancer Cell International|March 3, 2021
LINC01089 functions as a ceRNA for miR-152-3p to inhibit non-small lung cancer progression through regulating PTENHuixian Zhang, Hao Zhang, Xingya Li, et al.
Frontiers in Neurology|January 28, 2026
High-stimulation-rate ABR predicts persistent auditory pathway dysfunction in neonates with severe hyperbilirubinemia: a 6-month longitudinal studyYuanquan Li, Qingchun Pan, Xingya Li, et al.
Medicine|July 21, 2023
Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patientsHuixian Zhang, Xingya Li, Ziheng Zhang, et al.
Frontiers in Oncology|April 18, 2022
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future PerspectiveNingning Yan, Sanxing Guo, Huixian Zhang, et al.
Frontiers in Pharmacology|September 18, 2023
Successful treatment of lung adenocarcinoma complicated with a rare compound <i>EGFR</i> mutation L833V/H835L using aumolertinib: a case report and literature reviewLinlin Li, Siyuan Huang, Liying Qin, et al.
Cancer Medicine|May 26, 2022
Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidenceYurong Wang, Shujing Shen, Peizhu Hu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 27, 2019
[Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung 
Adenocarcinoma]Panhua Li, Banban Li, Yunshu Shi, et al.
BMC Cancer|November 14, 2021
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790MYurong Wang, Ruipan Zheng, Peizhu Hu, et al.
Pageof 15

Showing results (21-30 of 146) with videos related to

Sort By:
Pageof 15
Immunology|August 18, 2004
Thymocytes induced by antigen injection into the anterior chamber activate splenic CD8+ suppressor cells and enhance the antigen-induced production of immunoglobulin G1 antibodiesXingya Li, Yafei Wang, David Urso, et al.
Immunology|October 21, 2006
The suppression of delayed-type hypersensitivity by CD8+ regulatory T cells requires interferon-gammaRobert E Cone, Xingya Li, Roshanak Sharafieh, et al.
Cancer Cell International|March 3, 2021
LINC01089 functions as a ceRNA for miR-152-3p to inhibit non-small lung cancer progression through regulating PTENHuixian Zhang, Hao Zhang, Xingya Li, et al.
Frontiers in Neurology|January 28, 2026
High-stimulation-rate ABR predicts persistent auditory pathway dysfunction in neonates with severe hyperbilirubinemia: a 6-month longitudinal studyYuanquan Li, Qingchun Pan, Xingya Li, et al.
Medicine|July 21, 2023
Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patientsHuixian Zhang, Xingya Li, Ziheng Zhang, et al.
Frontiers in Oncology|April 18, 2022
BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future PerspectiveNingning Yan, Sanxing Guo, Huixian Zhang, et al.
Frontiers in Pharmacology|September 18, 2023
Successful treatment of lung adenocarcinoma complicated with a rare compound <i>EGFR</i> mutation L833V/H835L using aumolertinib: a case report and literature reviewLinlin Li, Siyuan Huang, Liying Qin, et al.
Cancer Medicine|May 26, 2022
Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidenceYurong Wang, Shujing Shen, Peizhu Hu, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 27, 2019
[Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung 
Adenocarcinoma]Panhua Li, Banban Li, Yunshu Shi, et al.
BMC Cancer|November 14, 2021
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790MYurong Wang, Ruipan Zheng, Peizhu Hu, et al.
Pageof 15